Info

🌱 來自: 2018 ACC AHA Cholesterol Guidelines

secondary prevention of clinical ascvd in patients with preexisting occlusive vascular disease

Age ≤75 without safety concerns

High- or maximally tolerated intensity statin to achieve LDL-C lowering of 50% or greater

Age ≥75 years

Start moderate- or high-intensity statin therapy after evaluation of the potential ASCVD reduction, frailty, and drug interactions

Any patient with concern for statin intolerance

Moderate-intensity statin therapy with aim to achieve 30% to 49% reduction in LDL-C